Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany

Table 4 Results from structural sensitivity analyses (discounted)

a: Extreme scenarios and variations in the duration of stable VE
	Base-case			Extreme scenario
				Best case	Worst case
ICER by outcome
€/HZ-case avoided	1,419			17	4,595
€/PHN-case avoided	20,809			163	327,691
€/QALY gained	28,146			235	157,845
b: Duration of stable VE [years]
	0	5	10 (base-case)	15	20
ICER by outcome
€/HZ-case avoided	2,633	1,800	1,419	1,225	1,123
€/PHN-case avoided	40,300	27,057	20,809	17,708	16,128
€/QALY gained	53,702	36,211	28,146	24,060	21,931
c: Booster scenarios [by age at vaccination in years]
	Base-case	Best case
		50	60	70	80
ICER by outcome
€/HZ-case avoided	1,419	1,080	1,361	2,701	9,372
€/PHN-case avoided	20,809	19,001	19,632	22,931	35,604
€/QALY gained	28,146	30,241	32,173	46,126	93,497
	Base-case	Worst case
		50	60	70	80
ICER by outcome
€/HZ-case avoided	1,419	1,580	1,621	2,792	9,384
€/PHN-case avoided	20,809	29,095	22,643	23,345	35,619
€/QALY gained	28,146	52,628	39,604	47,559	93,565
d: Variations in the length of PHN [month]
	6	9 (base-case)	15	36
ICER by outcome
€/QALY gained	31,741	28,146	23,048	4,149

€, Euro in 2010 price level.ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year; VE, vaccine efficacy.

ISSN: 1472-6963